<turbo-stream action="append" target="audio_clips_list"><template>
    <hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8870299-the-biopharm-brief-data-driven-trial-design-and-bispecific-checkpoint-immunotherapy-advance-onco"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43486931/75x75/c 75w, https://audioboom.com/i/43486931/150x150/c 150w, https://audioboom.com/i/43486931/300x300/c 300w, https://audioboom.com/i/43486931/600x600/c 600w, https://audioboom.com/i/43486931/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43486931/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Data-Driven Trial Design and Bispecific Checkpoint Immunotherapy Advance Oncology Development
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
In today’s podcast, integrated biomarker modeling and dual-pathway immune checkpoint modulation highlight evolving strategies to improve translational efficiency and durability in oncology trials.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1772746293" data-format="short_date">Mar 05</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8869493-the-biopharm-brief-new-glioblastoma-combo-immunotherapy-advances-adaptive-neuro-oncology-trials"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43486931/75x75/c 75w, https://audioboom.com/i/43486931/150x150/c 150w, https://audioboom.com/i/43486931/300x300/c 300w, https://audioboom.com/i/43486931/600x600/c 600w, https://audioboom.com/i/43486931/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43486931/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: New Glioblastoma Combo Immunotherapy Advances Adaptive Neuro-Oncology Trials
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Welcome to The BioPharm Brief, your daily snapshot of key developments in biopharmaceutical research and clinical innovation. Today we’re looking at a new collaborative immunotherapy approach for one of the most challenging solid tumors, glioblastoma multiforme, and what it could mean for future neuro‑oncology strategies.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1772654439" data-format="short_date">Mar 04</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8866225-the-biopharm-brief-strategic-partnerships-cgt-infrastructure-and-triple-agonist-metabolic-inno"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43486931/75x75/c 75w, https://audioboom.com/i/43486931/150x150/c 150w, https://audioboom.com/i/43486931/300x300/c 300w, https://audioboom.com/i/43486931/600x600/c 600w, https://audioboom.com/i/43486931/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43486931/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Strategic Partnerships, CGT Infrastructure, and Triple-Agonist Metabolic Innovation Drive Drug Development Evolution
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Welcome to The BioPharm Brief, your daily overview of the scientific, operational, and strategic developments shaping today’s biopharmaceutical industry. Today’s coverage highlights how collaboration models, advanced therapy infrastructure, and next-generation metabolic science are evolving together as companies work to manage increasing development complexity across modern drug pipelines.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1772048953" data-format="short_date">Feb 25</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8865579-the-biopharm-brief-trial-recruitment-challenges-and-reshaping-workforce-strategies"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43486931/75x75/c 75w, https://audioboom.com/i/43486931/150x150/c 150w, https://audioboom.com/i/43486931/300x300/c 300w, https://audioboom.com/i/43486931/600x600/c 600w, https://audioboom.com/i/43486931/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43486931/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Trial Recruitment Challenges and Reshaping Workforce Strategies
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Welcome to The BioPharm Brief, where we break down the latest developments shaping biopharmaceutical research, clinical progress, and industry strategy. Today’s podcast looks at how clinical trial realities and workforce evolution continue to influence drug development decisions and the future adoption of advanced therapies across the industry.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1771968425" data-format="short_date">Feb 24</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8865010-the-biopharm-brief-long-term-clinical-durability-advances-rare-disease-treatment-strategies"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43486931/75x75/c 75w, https://audioboom.com/i/43486931/150x150/c 150w, https://audioboom.com/i/43486931/300x300/c 300w, https://audioboom.com/i/43486931/600x600/c 600w, https://audioboom.com/i/43486931/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43486931/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Long-Term Clinical Durability Advances Rare Disease Treatment Strategies
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Today’s podcast highlights how sustained clinical efficacy data in alpha-thalassemia and ulcerative colitis highlight durability as a defining benchmark in modern biologic drug development.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1771882455" data-format="short_date">Feb 23</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>
<hr class="mvn mhs text-black-50 opacity-25">
<div class="card rounded-0 border-0 pas qa-audio-clip-overview" style="--bs-card-bg: transparent;">
<a class="text-decoration-none" href="/posts/8864090-the-biopharm-brief-regulatory-shifts-rare-disease-innovation-and-precision-drug-development-tr"><div class="Episode-list-grid card-body pan">
<div class="l-flex align-items-baseline gap-2 gap-md-3">
<img srcset="https://audioboom.com/i/43486931/75x75/c 75w, https://audioboom.com/i/43486931/150x150/c 150w, https://audioboom.com/i/43486931/300x300/c 300w, https://audioboom.com/i/43486931/600x600/c 600w, https://audioboom.com/i/43486931/1400x1400/c 1400w" sizes="(max-width: 400px) 64px, 96px" style="background-color: #0d0d0d; max-width: 96px; width: 15cqw;" class="js-img-bg ratio-square rounded-1" loading="lazy" src="https://audioboom.com/i/43486931/1400x1400/c" />
<div class="vstack gap-1 my-auto">
<h5 class="text-line-clamp text-line-clamp-3 balanced-h fs-6 fs-5-lg fw-normal mb-0">
The BioPharm Brief: Regulatory Shifts, Rare Disease Innovation, and Precision Drug Development Trends
</h5>
<div class="text-line-clamp text-line-clamp-3 balanced-p fs-8 text-muted text-break">
Today’s BioPharm Brief highlights key regulatory, clinical, and therapeutic development updates shaping the biopharma landscape. Recent coverage from BioPharm International reflects how evolving clinical science, rare disease innovation, and regulatory modernization continue to influence drug development strategy and approval pathways across the industry.
</div>
<div class="text-muted df align-items-baseline gap-2 fs-8">
<span class="numeric-tabular d-sm-none">
2m
</span>
<span class="d-sm-none">
&bull;
</span>
<span><span class="js-time" data-epochtime="1771626176" data-format="short_date">Feb 20</span></span>
</div>
</div>
</div>
<div class="d-none d-sm-grid" style="justify-self: center; align-items: center;">
<div class="fs-8 numeric-tabular text-nowrap text-muted phs">
2m
</div>
</div>
</div>
</a></div>

</template></turbo-stream>
  <turbo-stream action="remove" target="turbo_pagination"></turbo-stream>
